RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis

Journal of Cellular Physiology

Volumn 228, Issue 8, 2013, Pages 1676-1687

  Di Fiore, Riccardo ^a   D'Anneo, Antonella ^a   Tesoriere, Giovanni ^b   Vento, Renza ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P107; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR E2F5; TRANSCRIPTION FACTOR E2F6; UNCLASSIFIED DRUG; UVOMORULIN;

ALLELE; ANEUPLOIDY; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME SEGREGATION; CHROMOSOME TRANSLOCATION; DIMERIZATION; DNA DAMAGE; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EXON; G1 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HUMAN; INTRON; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; EYE NEOPLASMS; GENE SILENCING; HUMANS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION;

EID: 84876723158     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24329     Document Type: Review

References (134)

1. Abramson DH. 2005. Retinoblastoma in the 20th century: Past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci 46:2683-2691.
2. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. 2000. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 20:3633-3639.
3. Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P, Saavedra HI. 2010. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol 30:694-710.
4. Akin H, Yilmazbayhan D, Kiliçaslan Z, Dilege S, Doǧan O, Toker A, Kalayci G. 2002. Clinical significance of P16INK4A and retinoblastoma proteins in non-small-cell lung carcinoma. Lung Cancer 38:253-260.
5. Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34:369-376.
6. Alonso J, GarcÃa-Miguel P, Abelairas J, Mendiola M, Pesta ÃA. 2001. A microsatellite fluorescent method for linkage analysis in familial retinoblastoma and deletion detection at the RB1 locus in retinoblastoma and osteosarcoma. Diagn Mol Pathol 10:9-14.
7. Aoki I, Higuchi M, Gotoh Y. 2012. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene DOI: 10.1038/onc.2012.428. (In Press).
8. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, Taya Y. 2008. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 68:5104-5112.
9. Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T, Kuninaka S, Shibata T, Ohata H, Nakagama H, Taya Y, Saya H. 2012. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 287:7896-7906.
10. Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, Steensgaard P, Wagener C, Sardet C, Moroni MC, Helin K. 2005. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem 280:1199-1208.
11. Bamne MN, Ghule PN, Jose J, Banavali SD, Kurkure PA, Amare Kadam PS. 2005. Constitutional and somatic RB1 mutation spectrum in nonfamilial unilateral and bilateral retinoblastoma in India. Genet Test 9:200-211.
12. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. 2003. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100:15601-15606.
13. Berman SD, Yuan TL, Miller ES, Lee EY, Caron A, Lees JA. 2008. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 6:1440-1451.
14. Boehm JS, Hession MT, Bulmer SE, Hahn WC. 2005. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol 25:6464-6474.
15. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL. 1999. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 5:2810-2819.
16. Bracken AP, Ciro M, Cocito A, Helin K. 2004. E2F target genes: Unraveling the biology. Trends Biochem Sci 29:409-417.
17. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601.
18. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, Phillips RA. 1995. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 15:3256-3265.
19. Canhoto AJ, Chestukhin A, Litovchick L, DeCaprio JA. 2000. Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells. Oncogene 19:5116-5122.
20. Chan HM, Smith L, La Thangue NB. 2001. Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene 20:6152-6163.
21. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ. 2004. Hyperphosphorylation of pRb: A mechanism for RB tumor suppressor pathway inactivation in bladder cancer. J Pathol 203:762-770.
22. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549-4553.
23. Chen HZ, Tsai SY, Leone G. 2009. Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer 9:785-797.
24. Chin L, Hahn WC, Getz G, Meyerson M. 2011. Making sense of cancer genomic data. Genes Dev 25:534-555.
25. Chong JL, Wenzel PL, Sáenz-Robles MT, Nair V, Ferrey A, Hagan JP, Gomez YM, Sharma N, Chen HZ, Ouseph M, Wang SH, Trikha P, Culp B, Mezache L, Winton DJ, Sansom OJ, Chen D, Bremner R, Cantalupo PG, Robinson ML, Pipas JM, Leone G. 2009. E2f 1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462:930-934.
26. Chow KN, Starostik P, Dean DC. 1996. The Rb family contains a conserved cyclin-dependent-kinase-regulated transcriptional repressor motif. Mol Cell Biol 16:7173-7181.
27. Classon M, Dyson N. 2001. p107 and p130: Versatile proteins with interesting pockets. Exp Cell Res 264:135-147.
28. Claudio PP, De Luca A, Howard CM, Baldi A, Firpo EJ, Koff A, Paggi MG, Giordano A. 1996. Functional analysis of pRb2/p130 interaction with cyclins. Cancer Res 56:2003-2008.
29. Claudio PP, Tonini T, Giordano A. 2002. The retinoblastoma family: Twins or distant cousins? Genome Biol 3:1-9.
30. Cobrinik D. 2005. Pocket proteins and cell cycle control. Oncogene 24:2796-2809.
31. Collins VP. 1995. Gene amplification in human gliomas. Glia 15:289-296.
32. Conkrite K, Sundby M, Mu D, Mukai S, Macpherson D. 2012. Cooperation between Rb and Arf in suppressing mouse retinoblastoma. J Clin Invest 122:1726-1733.
33. Corson TW, Gallie BL. 2007. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46:617-634.
34. D'Andrilli G, Masciullo V, Bagella L, Tonini T, Minimo C, Zannoni GF, Giuntoli RL, II, Carlson JA, Jr., Soprano DR, Soprano KJ, Scambia G, Giordano A. 2004. Frequent loss of prb2/p130 in human ovarian carcinoma. Clin Cancer Res 10:3098-3103.
35. D'Andrilli G, Giordano A, Bovicelli A. 2008. Epithelial ovarian cancer: The role of cell cycle genes in the different histotypes. Open Clin Cancer J 7:7-12.
36. D'Anneo A, Augello G, Santulli A, Giuliano M, di Fiore R, Messina C, Tesoriere G, Vento R. 2010. Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt. J Cell Physiol 222:433-443.
37. De Blasio A, Messina C, Santulli A, Mangano V, Di Leonardo E, D'Anneo A, Tesoriere G, Vento R. 2005. Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells. FEBS Lett 579:615-620.
38. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol AO, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L. 2007. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 110:1301-1307.
39. Dean JL, McClendon AK, Stengel KR, Knudsen ES. 2010. Modeling the effect of the RB tumor suppressor on disease progression: Dependence on oncogene network and cellular context. Oncogene 29:68-80.
40. DeCaprio JA. 2009. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 384:274-284.
41. Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS, Teng XM, Zhang X, Huang J, Han ZG. 2010. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res 70:782-791.
42. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson TW, Eagle RC, Jr., Squire JA, Gallie BL. 2008. Loss of RB1 induces non-proliferative retinoma: Increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 17:1363-1372.
43. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511.
44. Drago-Ferrante R, Santulli A, Di Fiore R, Giuliano M, Calvaruso G, Tesoriere G, Vento R. 2008. Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol 33:677-687.
45. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP. 1994. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79:119-130.
46. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756-784.
47. D'Urso V, Collodoro A, Mattioli E, Giordano A, Bagella L. 2010. Cytometry and DNA ploidy: Clinical uses and molecular perspective in gastric and lung cancer. J Cell Physiol 222:532-539.
48. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262.
49. Falls H, Neel J. 1951. Genetic of retinoblastoma. AMA Arch Ophthalmol 46:367-389.
50. Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S, Thyss A, Hofman P, Terrier P, Kalifa C, Brunat-Mentigny M, Patricot LM, Oberling F. 1996. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14:467-472.
51. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
52. Ganguly A, Shields CL. 2010. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 16:1292-1303.
53. Gaubatz S, Wood JG, Livingston DM. 1998. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci USA 95:9190-9195.
54. Gaubatz S, Lees JA, Lindeman GJ, Livingston DM. 2001. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol Cell Biol 21:1384-1392.
55. Genovese C, Trani D, Caputi M, Claudio PP. 2006. Cell cycle control and beyond: Emerging roles for the retinoblastoma gene family. Oncogene 25:5201-5209.
56. Giuliano M, Vento R, Lauricella M, Calvaruso G, Carabillo M, Tesoriere G. 1996. Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells. Eur J Biochem 236:523-532.
57. Godbout R, Dryja TP, Squire J, Gallie BL, Phillips RA. 1983. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 304:451-453.
58. Gouyer V, Gazzéri S, Bolon I, Drevet C, Brambilla C, Brambilla E. 1998. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 18:188-196.
59. Haller F, Löbke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sültmann H, Poustka A, Korf U, Füzesi L. 2008. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumors (GISTs). J Pathol 215:253-262.
60. Hansen MF, Cavenee WK. 1987. Perspectives in cancer research genetics of cancer predisposition. Cancer Res 47:5518-5527.
61. He F, Mo L, Zheng XY, Hu C, Lepor H, Lee Eva YHP, Sun TT, Wu XR. 2009. Deficiency of prb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 69:9413-9421.
62. Henley SA, Dick FA. 2012. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 7:10.
63. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6:177-185.
64. Higgins MJ, Hansen MF, Cavenee WK, Lalande M. 1989. Molecular detection of chromosomal translocations that disrupt the putative retinoblastoma susceptibility locus. Mol Cell Biol 9:1-5.
65. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van't Veer LJ, Bernards R. 1995. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 15:3082-3089.
66. Hill R, Song Y, Cardiff RD, Van Dyke T. 2005. Heterogeneous tumor evolution initiated by loss of prb function in a preclinical prostate cancer mode. Cancer Res 65:10243-10254.
67. Hong FD, Huang HJ, To H, Young LJ, Oro A, Bookstein R, Lee EY, Lee WH. 1989. Structure of the human retinoblastoma gene. Proc Natl Acad Sci USA 86:5502-5506.
68. Hu QJ, Dyson N, Harlow E. 1990. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9:1147-1155.
69. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. 2008. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumors with 6p22 amplification. Oncogene 27:2716-2727.
70. Indovina P, Acquaviva A, De Falco G, Rizzo V, Onnis A, Luzzi A, Giorgi F, Hadjistilianou T, Toti P, Tomei V, Pentimalli F, Carugi A, Giordano A. 2010. Downregulation and aberrant promoter methylation of p16INK4A: A possible novel heritable susceptibility marker to retinoblastoma. J Cell Physiol 223:143-150.
71. Infante A, Laresgoiti U, Fernández-Rueda J, Fullaondo A, Galán J, Díaz-Uriarte R, Malumbres M, Field SJ, Zubiaga AM. 2008. E2F2 represses cell cycle regulators to maintain quiescence. Cell Cycle 7:3915-3927.
72. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC. 2012. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 136:277-293.
73. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. 1993. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541.
74. Kim LH, Peh SC, Poppema S. 2006. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: Relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death. Hum Pathol 37:92-100.
75. Knudsen ES, Knudsen KE. 2006. Retinoblastoma tumor suppressor: Where cancer meets the cell cycle. Exp Biol Med 231:1271-1281.
76. Knudson AG, Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
77. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M. 2010. E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer 10:64.
78. Lalande M, Dryja TP, Schreck RR, Shipley J, Flint A, Latt SA. 1984. Isolation of human chromosomes 13-specific DNA sequences cloned from flow-sorted chromosomes and potentially linked to the retinoblastoma locus. Cancer Genet Cytogenet 13:283-295.
79. Lammens T, Li J, Leone G, De Veylder L. 2009. Atypical E2Fs: New players in the E2F transcription factor family. Trends Cell Biol 19:111-118.
80. Lavia P, Mileo AM, Giordano A, Paggi MG. 2003. Emerging roles of DNA tumor viruses in cell proliferation: New insights into genomic instability. Oncogene 22:6508-6516.
81. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399.
82. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N, Helin K. 1993. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13:7813-7825.
83. Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, Cleghorn W, Chen HZ, Kornacker K, Liu CG, Pandit SK, Khanizadeh M, Weinstein M, Leone G, de Bruin A. 2008. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell 14:62-75.
84. Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA. 2007. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell 26:539-551.
85. Liu W, Lv G, Li Y, Li L, Wang B. 2011. Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. J Exp Clin Cancer Res 30:76-82.
86. Logan N, Delavaine L, Graham A, Reilly C, Wilson J, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB. 2004. E2F-7: A distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene 23:5138-5150.
87. Macpherson D. 2008. Insights from mouse models into human retinoblastoma. Cell Div 3:9.
88. Maeta Y, Shiotab G, Okanoa J, Murawakia Y. 2005. Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells. Tumour Biol 26:300-305.
89. Masciullo V, Berardengo E, Boglione A, Sgambato A, Bernardi A, Forni M, Linari A, Cito L, Scambia G, Comandone A, Giordano A. 2008. The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas. Clin Cancer Res 14:4775-4779.
90. Moberg K, Starz MA, Lees JA. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16:1436-1449.
91. Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A, Kaye FJ. 2000. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 19:4632-4639.
92. Monteiro AN. 2003. BRC A1: The enigma of tissue-specific tumor development. Trends Genet 19:312-315.
93. Moon NS, Dyson N. 2008. E2F7 and E2F8 keep the E2F family in balance. Dev Cell 14:1-3.
94. Moran E. 1993. Interaction of adenoviral proteins with pRB and p53. FASEB J 7:880-885.
95. Na-Hye M. 2008. Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res Treat 40:45-52.
96. Neganova I, Lako M. 2008. G1 to S phase cell cycle transition in somatic and embryonic stem cells. J Anat 213:30-44.
97. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. 1998. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack rb alterations. Am J Pathol 153:159-163.
98. Oberley MJ, Inman DR, Farnham PJ. 2003. E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9. J Biol Chem 278:42466-42476.
99. Parisi T, Bronson RT, Lees JA. 2009. Inhibition of pituitary tumors in Rb mutant chimeras through E2f4-loss reveals a key suppressive role for the pRB/E2F pathway in urothelium and ganglionic carcinogenesis. Oncogene 28:500-508.
100. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, Gronchi A, Pierotti MA, Pilotti S. 2005. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 104:159-169.
101. Pipinikas CP, Nair SB, Kirby RS, Carter ND, Fenske CD. 2007. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: A preliminary study. Biomarkers 12:541-557.
102. Plisiecka-Hałasa J, Dansonka-Mieszkowska A, Kraszewska E, Dańska-Bidzińska A, Kupryjańczyk J. 2008. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas. Anticancer Res 28:989-996.
103. Pohlers M, Truss M, Frede U, Scholz A, Strehle M, Kuban RJ, Hoffmann B, Morkel M, Birchmeier C, Hagemeier C. 2005. A Role for E2F6 in the restriction of male-germ-cell-specific gene expression. Curr Biol 15:1051-1057.
104. Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ, Johnson DG. 2010. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog 49:152-156.
105. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. 2004. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6:171-183.
106. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG. 2007. Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13:144-151.
107. Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Panton R, Branco P, Gallie B. 2003. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 72:253-269.
108. Rizzolio F, Caligiuri I, Lucchetti C, Fratamico R, Tomei V, Gallo G, Agelan A, Ferrari G, Toffoli G, Klein-Szanto AJ, Giordano A. 2013. Dissecting Pin1 and phospho-pRb regulation. J Cell Physiol 228:73-77.
109. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H. 1998. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 12:1599-1609.
110. Sage J, Straight AF. 2010. RB's original CIN? Genes Dev 24:1329-1333.
111. Sellers WR, Kaelin WG, Jr. 1997. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15:3301-3312.
112. Sharpless NE, DePinho RA. 1999. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9:22-30.
113. Shi Y, Yang S, Troup S, Lu X, Callaghan S, Park D, Xing Y, Yang X. 2011. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep 25:1713-1719.
114. Simin K, Wu H, Lu L, Pinkel D, Albertson D, Cardiff RD, Van Dyke T. 2004. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol 2:194-205.
115. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. 2008. Cancer risk in patients with constitutional chromosome deletions: A nationwide British cohort study. Br J Cancer 98:1929-1933.
116. Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S. 2012. Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72:4141-4153.
117. Teissier S, Pang CL, Thierry F. 2010. The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells. Oncogene 29:5061-5070.
118. Valverde JR, Alonso J, Palacios I, Pestaña A. 2005. RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet 6:53.
119. Vogel F. 1979. Genetics of retinoblastoma. Hum Genet 52:1-54.
120. Wang JY, Knudsen ES, Welch PJ. 1994. The retinoblastoma tumor suppressor protein. Adv Cancer Res 64:25-85.
121. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. 2006. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736-747.
122. Wenzel PL, Wu L, de Bruin A, Chong JL, Chen W-Y, Dureska G, Sites E, Pan T, Sharma A, Huang K, Ridgway R, Mosaliganti K, Sharp R, Machiraju R, Saltz J, Yamamoto H, Cross JC, Robinson ML, Leone G. 2007. Rb is critical in a mammalian tissue stem cell population. Genes Dev 21:85-97.
123. Westendorp B, Mokry M, Groot Koerkamp MJ, Holstege FC, Cuppen E, de Bruin A. 2012. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res 40:3511-3523.
124. Williams BO, Remington L, Albert DM, Mukai S, Roderick T, Bronson RT, Jacks T. 1994a. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484.
125. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T. 1994b. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 13:4251-4259.
126. Williams JP, Stewart T, Li B, Mulloy R, Dimova D, Classon M. 2006. The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol 26:1170-1182.
127. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
128. Worku D, Jouhra F, Jiang GW, Patani N, Newbold RF, Mokbel K. 2008. Evidence of a tumour suppressive function of E2F1 gene in human breast cancer. Anticancer Res 28:2135-2139.
129. Wu Z, Yu Q. 2009. E2F1-mediated apoptosis as a target of cancer therapy. Curr Mol Pharmacol 2:149-160.
130. Wu L, de Bruin A, Saavedra HI, Starovic M, Trimboli A, Yang Y, Opavska J, Wilson P, Thompson JC, Ostrowski MC, Rosol TJ, Woollett LA, Weinstein M, Cross JC, Robinson ML, Leone G. 2003. Extra-embryonic function of Rb is essential for embryonic development and viability. Nature 421:942-947.
131. Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, Zhu WG, Wu M. 2006. Novel link between E2F1 and Smac/DIABLO: Proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res 34:2046-2055.
132. Xiong Y, Zhang H, Beach D. 1993. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572-1583.
133. Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW. 2012. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci USA 109:8212-8217.
134. Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T. 1988. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3:471-475.